Anjiolab Pursuing KOSDAQ Listing Obtains US Patent for Phenol Use

[Asia Economy Reporter Lim Jeong-su] Anjiolab, a KOSDAQ-listed KONEX bio company, announced that it has obtained a US patent for the use of paeonol to inhibit angiogenesis and enhance radiosensitivity.

According to Anjiolab on the 21st, the patent received from the US Patent and Trademark Office involves developing a radiosensitizer that enhances the effect of radiation therapy and reduces side effects by utilizing paeonol. Paeonol is known to have angiogenesis inhibitory effects. When an angiogenesis inhibitor is administered together with radiation therapy, the radiation dose and the toxicity of radiation treatment can be reduced.

Paeonol is one of the active ingredients in peony or tree peony and has various effects such as antibacterial, anti-inflammatory, analgesic, and immune enhancement. It was confirmed that radiosensitivity increases when paeonol, which has angiogenesis inhibitory effects, is co-administered during radiation exposure. It is known that radiosensitivity increased with paeonol treatment in 'lung cancer cell lines' and 'cervical cancer cell lines,' resulting in a significant decrease in cancer cell survival rates.

An Anjiolab official said, "This patent concerns the 'use of paeonol for angiogenesis inhibition or enhancement of radiosensitivity,'" adding, "We plan to continuously conduct research and development for effective cancer treatment, including the verified patented technology."

Meanwhile, Anjiolab changed its KOSDAQ listing underwriter from NH Investment & Securities to Daishin Securities on the 1st. Marking this change, the company will actively prepare for the KOSDAQ listing and plans to reapply for a technology evaluation in the second half of this year.

This content was produced with the assistance of AI translation services.